Table 1. Anti-PD-1: immune-related pneumonitis management guidance.
Management guidance |
Grade 1 |
Continue anti-PD-1 with monitoring |
If pneumonitis is suspected, evaluate with radiographic imaging |
Grade 2 |
Withhold anti-PD-1 |
Consider pulmonary consultation with bronchoscopy and biopsy, along with ID consult |
Conduct an in-person evaluation approx. twice per week and consider frequent chest X-rays |
Administer corticosteroids |
Upon improvement to grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month |
Discontinue anti-PD-1 if upon re-challenge patient develops a second episode of grade 2 or higher pneumonitis |
Grade 3 and 4 |
Discontinue anti-PD-1 |
Consider pulmonary function tests with pulmonary consultation |
Bronchoscopy with biopsy and/or BAL is recommended |
Treat with IV steroids; when symptoms improve to grade 1 or less, administer oral steroids, then initiate taper over at least 1 month |
Add prophylactic antibiotics for opportunistic infections* |
If IV steroids followed by oral steroids does not reduce initial symptoms within 48 to 72 h, treat with infliximab at 5 mg/kg once every 2 weeks; discontinue upon symptom relief and initiate a prolonged steroid taper over 45 to 60 days |
*, Add anti-inflammatory drugs—antibiotics, antifungal agents 1, except the most common infections (such as viral and bacterial), consider to exclude Legionella and Pneumocystis carinii.